Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

• Bruno Dubois,
• Jesús López‑Arrieta,
• Stanley Lipschitz,
• Triantafyllos Doskas,
• Luiza Spiru,
• Svitlana Moroz,
• Olena Venger,
• Patrick Vermersch,
• Alain Moussy,
• Colin D. Mansfield,
• Olivier Hermine,
• Magda Tsolaki,
• for the AB09004 Study Group Investigators

Affiliations

Bruno Dubois

Alzheimer Research Center IM2A, Salpêtrière Hospital, AP-HP, Sorbonne University

Jesús López‑Arrieta

Cantoblanco Memory Clinic, Geriatric Department, Hospital Cantoblanco

Stanley Lipschitz

The Dr Stanley Lipschitz Clinic Inc, Rosebank

Triantafyllos Doskas

Neurological Department, Athens Naval Hospital

Luiza Spiru

Carol Davila University of Medicine and Pharmacy, The Excellence Clinic of Geriatrics, Gerontology and Old Age Psychiatry

Svitlana Moroz

Psychosomatic Center Based On Psychoneurology Department of Communal Enterprise ‘Dnipropetrovsk Regional Clinical Hospital Named After I.I. Mechnikov’, Dnipropetrovsk Regional Council

Olena Venger

Department Psychiatry, Narcology and Medical Psychology I, Horbachevsky Ternopil National Medical University

Patrick Vermersch

Univ. Lille, UMR Inserm U1172, CHU Lille, FHU Precise

Alain Moussy

AB Science

Colin D. Mansfield

AB Science

Olivier Hermine

AB Science

Magda Tsolaki

First Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki

for the AB09004 Study Group Investigators